Historical valuation data is not available at this time.
Realcan Pharmaceutical Group Co., Ltd. is a Chinese pharmaceutical company primarily engaged in the research, development, production, and sales of pharmaceutical products, including chemical drugs, traditional Chinese medicines, and medical devices. The company operates through its subsidiaries and has a presence in both domestic and international markets. Its core business segments include pharmaceutical manufacturing, distribution, and retail pharmacy services. Realcan's competitive advantages lie in its integrated pharmaceutical industry chain, which spans from R&D to end-user sales, providing a comprehensive portfolio of healthcare products. The company focuses on treatments for common diseases such as cardiovascular, anti-infective, and digestive system disorders, leveraging its manufacturing capabilities and distribution network to maintain a stable market position within China's mid-tier pharmaceutical sector.
The company invests in R&D for generic drugs and improvements in traditional Chinese medicine formulations, though specific pipeline details or patent portfolios are not widely disclosed in English-language sources.
Realcan Pharmaceutical Group operates in a stable but competitive sector within China's pharmaceutical industry. The company benefits from integrated operations and a focus on essential medicines, though it faces regulatory and competitive pressures. Investment potential is moderated by limited transparency and earnings volatility. Risks include regulatory changes and market competition, suggesting a cautious approach without more detailed financial disclosures.